170 related articles for article (PubMed ID: 7540551)
1. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
Rudoni M; Antonini G; Favro M; Baroli A; Brambilla M; Cardani G; Ciardi L; Sacchetti GM; Inglese E
Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
[TBL] [Abstract][Full Text] [Related]
2. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
3. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
[TBL] [Abstract][Full Text] [Related]
4. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
[TBL] [Abstract][Full Text] [Related]
6. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
[TBL] [Abstract][Full Text] [Related]
7. [Bone scintigraphy findings in patients with recently diagnosed adenocarcinoma of the prostate: relationship with prostate specific antigen levels].
Ortega A; Alonso JC; Suárez M; Domínguez P; Almoguera I; Bittini A; Gómez A; Martínez L; Herranz F; Pérez-Vázquez JM
Rev Esp Med Nucl; 2000 Oct; 19(6):409-15. PubMed ID: 11060270
[TBL] [Abstract][Full Text] [Related]
8. Metastasis on bone scan with low prostate specific antigen (≤20 ng/ml) and Gleason's score (<8) in newly diagnosed Pakistani males with prostate cancer: should we follow Western guidelines?
Zaman MU; Fatima N; Sajjad Z
Asian Pac J Cancer Prev; 2011; 12(6):1529-32. PubMed ID: 22126493
[TBL] [Abstract][Full Text] [Related]
9. The value of a baseline bone scan in patients with newly diagnosed prostate cancer.
Lin K; Szabo Z; Chin BB; Civelek AC
Clin Nucl Med; 1999 Aug; 24(8):579-82. PubMed ID: 10439178
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
Wolff JM; Bares R; Jung PK; Buell U; Jakse G
Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
[TBL] [Abstract][Full Text] [Related]
11. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G
Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680
[TBL] [Abstract][Full Text] [Related]
12. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
[TBL] [Abstract][Full Text] [Related]
13. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
14. MRI of the skeleton in prostate cancer staging.
Rydh A; Lundblad M; Ahlström KR; Tavelin B; Stattin P
Scand J Urol Nephrol; 2003; 37(3):222-5. PubMed ID: 12775281
[TBL] [Abstract][Full Text] [Related]
15. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study.
Al-Ghazo MA; Ghalayini IF; Al-Azab RS; Bani-Hani I; Barham A; Haddad Y
Int Braz J Urol; 2010; 36(6):685-91; discussion 691-2. PubMed ID: 21176275
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
17. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
Haukaas S; Roervik J; Halvorsen OJ; Foelling M
Br J Urol; 1997 May; 79(5):770-6. PubMed ID: 9158517
[TBL] [Abstract][Full Text] [Related]
18. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients.
Lee N; Fawaaz R; Olsson CA; Benson MC; Petrylak DP; Schiff PB; Bagiella E; Singh A; Ennis RD
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1443-6. PubMed ID: 11121646
[TBL] [Abstract][Full Text] [Related]
19. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer.
Rydh A; Tomic R; Tavelin B; Hietala SO; Damber JE
Scand J Urol Nephrol; 1999 Apr; 33(2):89-93. PubMed ID: 10360447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
